{"id":"NCT00831415","sponsor":"Pfizer","briefTitle":"Study Evaluating Long-Term Safety of Desvenlafaxine Succinate Sustained Release With Japanese Adult Subjects in Major Depressive Disorder (MDD)","officialTitle":"A 10-Month Open-Label Evaluation Of The Long-Term Safety Of Desvenlafaxine Succinate Sustained Release In Japanese Adults With Major Depressive Disorder","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-03","primaryCompletion":"2011-03","completion":"2011-03","firstPosted":"2009-01-29","resultsPosted":"2012-01-30","lastUpdate":"2018-12-07"},"enrollment":304,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Major Depressive Disorder"],"interventions":[{"type":"DRUG","name":"desvenlafaxine succinate sustained release tablets","otherNames":["DVS-233; Pristiq"]}],"arms":[{"label":"1","type":"EXPERIMENTAL"}],"summary":"The primary objective of this study is to evaluate the long-term safety of desvenlafaxine succinate sustained release tablets during 10-month open-label treatment of Japanese subjects with major depressive disorder (MDD).\n\nThe secondary objective is to evaluate the long-term response of subjects receiving desvenlafaxine succinate sustained release tablets by clinical global evaluation, general well-being and absence of symptoms.","primaryOutcome":{"measure":"Change From Baseline in Hamilton Psychiatric Scale for Depression-17 Item (HAM-D17) Score","timeFrame":"Baseline (Extension Study) up to Day 308 or Final On-Therapy (FOT) Evaluation","effectByArm":[{"arm":"DVS SR","deltaMin":-4.76,"sd":null}],"pValues":[]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":1},"locations":{"siteCount":17,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":["https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=3151A1-3350"]},"adverseEventsSummary":{"seriousAny":{"events":8,"n":304},"commonTop":["Nasopharyngitis","Nausea","Somnolence","Dizziness","Headache"]}}